Edward M. Sellers - Publications

University of Toronto, Toronto, ON, Canada 
Mental Health, Social Psychology, Occupational Health and Safety

53 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Tyndale RF, Sellers EM. Opioids: The Painful Public Health Reality. Clinical Pharmacology and Therapeutics. 103: 924-935. PMID 29878319 DOI: 10.1002/cpt.1074  0.36
2016 Schoedel KA, Sun H, Sellers EM, Faulknor J, Levy-Cooperman N, Li X, Kennedy WP, Cha JH, Lewis NM, Liu W, Bondiskey P, McCrea JB, Panebianco DL, Troyer MD, Wagner JA. Assessment of the Abuse Potential of the Orexin Receptor Antagonist, Suvorexant, Compared With Zolpidem in a Randomized Crossover Study. Journal of Clinical Psychopharmacology. PMID 27253658 DOI: 10.1097/JCP.0000000000000516  0.36
2016 Coplan PM, Chilcoat HD, Butler SF, Sellers EM, Kadakia A, Harikrishnan V, Haddox JD, Dart RC. The Effect of an Abuse-Deterrent Opioid Formulation on Opioid Abuse-Related Outcomes in the Post-Marketing Setting. Clinical Pharmacology and Therapeutics. PMID 27170195 DOI: 10.1002/cpt.390  0.36
2014 Schoedel KA, Morrow SA, Sellers EM. Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect. Neuropsychiatric Disease and Treatment. 10: 1161-74. PMID 25061302 DOI: 10.2147/NDT.S30713  0.36
2014 Romach MK, Schoedel KA, Sellers EM. Human abuse liability evaluation of CNS stimulant drugs. Neuropharmacology. 87: 81-90. PMID 24793872 DOI: 10.1016/j.neuropharm.2014.04.014  0.36
2014 Cruz HG, Hoever P, Chakraborty B, Schoedel K, Sellers EM, Dingemanse J. Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users. Cns Drugs. 28: 361-72. PMID 24627301 DOI: 10.1007/s40263-014-0150-x  0.36
2014 Reches A, Levy-Cooperman N, Laufer I, Shani-Hershkovitch R, Ziv K, Kerem D, Gal N, Stern Y, Cukierman G, Romach MK, Sellers EM, Geva AB. Brain Network Activation (BNA) reveals scopolamine-induced impairment of visual working memory. Journal of Molecular Neuroscience : Mn. 54: 59-70. PMID 24535560 DOI: 10.1007/s12031-014-0250-6  0.36
2014 Harris SC, Perrino PJ, Smith I, Shram MJ, Colucci SV, Bartlett C, Sellers EM. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. Journal of Clinical Pharmacology. 54: 468-77. PMID 24243216 DOI: 10.1002/jcph.235  0.36
2013 Sellers EM, Schoedel K, Bartlett C, Romach M, Russo EB, Stott CG, Wright S, White L, Duncombe P, Chen CF. A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray. Clinical Pharmacology in Drug Development. 2: 285-94. PMID 27121791 DOI: 10.1002/cpdd.36  0.36
2013 Higgins GA, Sellers EM, Fletcher PJ. From obesity to substance abuse: therapeutic opportunities for 5-HT2C receptor agonists. Trends in Pharmacological Sciences. 34: 560-70. PMID 24041919 DOI: 10.1016/j.tips.2013.08.001  0.36
2012 Comer SD, Zacny JP, Dworkin RH, Turk DC, Bigelow GE, Foltin RW, Jasinski DR, Sellers EM, Adams EH, Balster R, Burke LB, Cerny I, Colucci RD, Cone E, Cowan P, et al. Core outcome measures for opioid abuse liability laboratory assessment studies in humans: IMMPACT recommendations. Pain. 153: 2315-24. PMID 22998781 DOI: 10.1016/j.pain.2012.07.035  0.36
2012 Schoedel KA, Addy C, Chakraborty B, Rosko K, Dunbar S, Maes A, Chen N, Stoch SA, Wagner J, Chodakewitz J, Sellers EM. Human abuse potential and cognitive effects of taranabant, a cannabinoid 1 receptor inverse agonist: a randomized, double-blind, placebo- and active-controlled, crossover study in recreational polydrug users. Journal of Clinical Psychopharmacology. 32: 492-502. PMID 22722508 DOI: 10.1097/JCP.0b013e31825d380d  0.36
2012 Pope LE, Schoedel KA, Bartlett C, Sellers EM. A study of potential pharmacokinetic and pharmacodynamic interactions between dextromethorphan/quinidine and memantine in healthy volunteers. Clinical Drug Investigation. 32: e1-15. PMID 22712629 DOI: 10.2165/11633850-000000000-00000  0.36
2012 Shram MJ, Quinn AM, Chen N, Faulknor J, Luong D, Sellers EM, Endrenyi L. Differences in the in vitro and in vivo pharmacokinetic profiles of once-daily modified-release methylphenidate formulations in Canada: examination of current bioequivalence criteria. Clinical Therapeutics. 34: 1170-81. PMID 22512898 DOI: 10.1016/j.clinthera.2012.02.010  0.36
2012 Schoedel KA, Pope LE, Sellers EM. Randomized open-label drug-drug interaction trial of dextromethorphan/quinidine and paroxetine in healthy volunteers. Clinical Drug Investigation. 32: 157-69. PMID 22283559 DOI: 10.2165/11599870-000000000-00000  0.36
2011 McMorn S, Schoedel KA, Sellers EM. Effects of low-dose opioids on cognitive dysfunction. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4342-3; author reply. PMID 21969492 DOI: 10.1200/JCO.2011.38.2309  0.36
2011 Schoedel KA, McMorn S, Chakraborty B, Potts SL, Zerbe K, Sellers EM. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users. Journal of Opioid Management. 7: 179-92. PMID 21823549 DOI: 10.5055/jom.2011.0061  0.36
2011 Schoedel KA, Chen N, Hilliard A, White L, Stott C, Russo E, Wright S, Guy G, Romach MK, Sellers EM. A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Human Psychopharmacology. 26: 224-36. PMID 21671456 DOI: 10.1002/hup.1196  0.36
2010 Schoedel KA, McMorn S, Chakraborty B, Zerbe K, Sellers EM. Reduced cognitive and psychomotor impairment with extended-release oxymorphone versus controlled-release oxycodone. Pain Physician. 13: 561-73. PMID 21102969  0.36
2010 Mansbach RS, Schoedel KA, Kittrelle JP, Sellers EM. The role of adverse events and related safety data in the pre-market evaluation of drug abuse potential. Drug and Alcohol Dependence. 112: 173-7. PMID 20817417 DOI: 10.1016/j.drugalcdep.2010.07.001  0.36
2010 Mwenifumbo JC, Zhou Q, Benowitz NL, Sellers EM, Tyndale RF. New CYP2A6 gene deletion and conversion variants in a population of Black African descent. Pharmacogenomics. 11: 189-98. PMID 20136358 DOI: 10.2217/pgs.09.144  0.36
2010 Zawertailo LA, Tyndale RF, Busto U, Sellers EM. Effect of metabolic blockade on the psychoactive effects of dextromethorphan. Human Psychopharmacology. 25: 71-9. PMID 20041473 DOI: 10.1002/hup.1086  0.36
2009 Johanson CE, Balster RL, Henningfield JE, Schuster CR, Anthony JC, Barthwell AG, Coleman JJ, Dart RC, Gorodetzky CW, O'Keeffe C, Sellers EM, Vocci F, Walsh SL. Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: expert panel report. Drug and Alcohol Dependence. 105: S65-71. PMID 19783383 DOI: 10.1016/j.drugalcdep.2009.08.006  0.36
2009 Al Koudsi N, Ahluwalia JS, Lin SK, Sellers EM, Tyndale RF. A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. The Pharmacogenomics Journal. 9: 274-82. PMID 19365400 DOI: 10.1038/tpj.2009.11  0.36
2008 Mwenifumbo JC, Sellers EM, Tyndale RF. Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descent. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. 10: 1319-25. PMID 18686179 DOI: 10.1080/14622200802238894  0.36
2008 Mwenifumbo JC, Al Koudsi N, Ho MK, Zhou Q, Hoffmann EB, Sellers EM, Tyndale RF. Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Human Mutation. 29: 679-88. PMID 18360915 DOI: 10.1002/humu.20698  0.36
2007 Parasrampuria DA, Schoedel KA, Schuller R, Gu J, Ciccone P, Silber SA, Sellers EM. Assessment of pharmacokinetics and pharmacodynamic effects related to abuse potential of a unique oral osmotic-controlled extended-release methylphenidate formulation in humans. Journal of Clinical Pharmacology. 47: 1476-88. PMID 17962423 DOI: 10.1177/0091270007308615  0.36
2007 Parasrampuria DA, Schoedel KA, Schuller R, Silber SA, Ciccone PE, Gu J, Sellers EM. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. Journal of Clinical Psychopharmacology. 27: 459-67. PMID 17873677 DOI: 10.1097/jcp.0b013e3181515205  0.36
2007 Mwenifumbo JC, Sellers EM, Tyndale RF. Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. Drug and Alcohol Dependence. 89: 24-33. PMID 17161559 DOI: 10.1016/j.drugalcdep.2006.11.012  0.36
2006 Malaiyandi V, Goodz SD, Sellers EM, Tyndale RF. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 15: 1812-9. PMID 17035386 DOI: 10.1158/1055-9965.EPI-05-0723  0.36
2006 Al Koudsi N, Mwenifumbo JC, Sellers EM, Benowitz NL, Swan GE, Tyndale RF. Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. European Journal of Clinical Pharmacology. 62: 481-4. PMID 16758265 DOI: 10.1007/s00228-006-0113-3  0.36
2005 Gilbert Evans SE, Ross LE, Sellers EM, Purdy RH, Romach MK. 3alpha-reduced neuroactive steroids and their precursors during pregnancy and the postpartum period. Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology. 21: 268-79. PMID 16373246 DOI: 10.1080/09513590500361747  0.36
2005 Mwenifumbo JC, Myers MG, Wall TL, Lin SK, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. Pharmacogenetics and Genomics. 15: 189-92. PMID 15861044  0.36
2005 Malaiyandi V, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clinical Pharmacology and Therapeutics. 77: 145-58. PMID 15735609 DOI: 10.1016/j.clpt.2004.10.011  0.36
2004 Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics. 14: 615-26. PMID 15475735 DOI: 10.1097/00008571-200409000-00006  0.36
2003 Sellers EM, Ramamoorthy Y, Zeman MV, Djordjevic MV, Tyndale RF. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. 5: 891-9. PMID 14668073 DOI: 10.1080/14622200310001615231  0.36
2003 Zawertailo LA, Busto UE, Kaplan HL, Greenblatt DJ, Sellers EM. Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital. Journal of Clinical Psychopharmacology. 23: 269-80. PMID 12826989 DOI: 10.1097/01.jcp.0000084031.22282.24  0.36
2003 Sellers EM, Tyndale RF, Fernandes LC. Decreasing smoking behaviour and risk through CYP2A6 inhibition. Drug Discovery Today. 8: 487-93. PMID 12818518 DOI: 10.1016/S1359-6446(03)02704-1  0.36
2003 Howard LA, Ahluwalia JS, Lin SK, Sellers EM, Tyndale RF. CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence. Pharmacogenetics. 13: 321-8. PMID 12777962 DOI: 10.1097/01.fpc.0000054090.48725.a2  0.36
2003 Zhang W, Ramamoorthy Y, Tyndale RF, Sellers EM. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 31: 768-72. PMID 12756210  0.36
2003 Micu AL, Miksys S, Sellers EM, Koop DR, Tyndale RF. Rat hepatic CYP2E1 is induced by very low nicotine doses: an investigation of induction, time course, dose response, and mechanism. The Journal of Pharmacology and Experimental Therapeutics. 306: 941-7. PMID 12750430 DOI: 10.1124/jpet.103.052183  0.36
2003 Schoedel KA, Sellers EM, Palmour R, Tyndale RF. Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. Molecular Pharmacology. 63: 96-104. PMID 12488541 DOI: 10.1124/mol.63.1.96  0.36
2002 Xu C, Goodz S, Sellers EM, Tyndale RF. CYP2A6 genetic variation and potential consequences. Advanced Drug Delivery Reviews. 54: 1245-56. PMID 12406643  0.36
2002 Ramamoorthy Y, Yu AM, Suh N, Haining RL, Tyndale RF, Sellers EM. Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochemical Pharmacology. 63: 2111-9. PMID 12110370  0.36
2002 Zhang W, Ramamoorthy Y, Tyndale RF, Glick SD, Maisonneuve IM, Kuehne ME, Sellers EM. Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 30: 663-9. PMID 12019193 DOI: 10.1124/dmd.30.6.663  0.36
2002 Pritzker D, Kanungo A, Kilicarslan T, Tyndale RF, Sellers EM. Designer drugs that are potent inhibitors of CYP2D6. Journal of Clinical Psychopharmacology. 22: 330-2. PMID 12006905  0.36
2002 Fernandes LC, Kilicarslan T, Kaplan HL, Tyndale RF, Sellers EM, Romach MK. Treatment of codeine dependence with inhibitors of cytochrome P450 2D6. Journal of Clinical Psychopharmacology. 22: 326-9. PMID 12006904  0.36
2002 Howard LA, Sellers EM, Tyndale RF. The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence. Pharmacogenomics. 3: 185-99. PMID 11972441 DOI: 10.1517/14622416.3.2.185  0.36
2002 Zhang W, Ramamoorthy Y, Kilicarslan T, Nolte H, Tyndale RF, Sellers EM. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 30: 314-8. PMID 11854151  0.36
2002 Tyndale RF, Sellers EM. Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. Therapeutic Drug Monitoring. 24: 163-71. PMID 11805739  0.36
1999 Busto UE, Zawertailo LA, Kaplan HL, Sellers EM. Identifying appropriate subjects for abuse liability studies using prestudy pharmacological testing. The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique. 6: 103-10. PMID 10519736  0.36
1998 Zawertailo LA, Kaplan HL, Busto UE, Tyndale RF, Sellers EM. Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study. Journal of Clinical Psychopharmacology. 18: 332-7. PMID 9690700 DOI: 10.1097/00004714-199808000-00014  0.36
1995 Zawertailo LA, Busto U, Kaplan HL, Sellers EM. Comparative abuse liability of sertraline, alprazolam, and dextroamphetamine in humans. Journal of Clinical Psychopharmacology. 15: 117-24. PMID 7782484 DOI: 10.1097/00004714-199504000-00007  0.36
Show low-probability matches.